Volume 29, Issue 6 pp. 1200-1206
Clinical Gastroenterology

Efficacy and safety of esomeprazole with flupentixol/melitracen in treating gastroesophageal reflux disease patients with emotional disorders

Yan-Yan Yu

Yan-Yan Yu

Department of Gastroenterology, Daping Hospital, Third Military Medical University, Chongqing, China

These authors contributed equally to this work.Search for more papers by this author
Dian-Chun Fang

Dian-Chun Fang

Department of Gastroenterology, Southwest Hospital, Third Military Medical University, Chongqing, China

These authors contributed equally to this work.Search for more papers by this author
Li-Lin Fan

Li-Lin Fan

Department of Gastroenterology, Daping Hospital, Third Military Medical University, Chongqing, China

Search for more papers by this author
Hui Chang

Hui Chang

Department of Gastroenterology, Daping Hospital, Third Military Medical University, Chongqing, China

Search for more papers by this author
Zhi-Lin Wu

Zhi-Lin Wu

Department of Gastroenterology, Daping Hospital, Third Military Medical University, Chongqing, China

Search for more papers by this author
Yan Cao

Yan Cao

Department of Gastroenterology, Daping Hospital, Third Military Medical University, Chongqing, China

Search for more papers by this author
Chun-Hui Lan

Corresponding Author

Chun-Hui Lan

Department of Gastroenterology, Daping Hospital, Third Military Medical University, Chongqing, China

Correspondence

Professor Chun-hui Lan, Department of Gastroenterology, Daping Hospital, Third Military Medical University, Chongqing 400042, China. Email: [email protected]

Search for more papers by this author
First published: 20 February 2014
Citations: 8
Declaration of personal interests: None.
Declaration of funding interests: This study was supported by a grant from the National Natural Science Foundation of China (No. 81171526) and the 2010 subject of the Third Military Medical University. All authors approved the final version of the article.

Abstract

Background and Aim

This study was designed to demonstrate the safety and efficacy of esomeprazole combined with flupentixol/melitracen for the treatment of gastroesophageal reflux disease (GERD) patients with emotional disorders.

Methods

Two hundred eighty-nine GERD patients with emotional disorders were divided randomly into two groups: group 1 received esomeprazole only (monotherapy) and group 2 received esomeprazole and flupentixol/melitracen (combination therapy). The patients' GERD questionnaire (GerdQ) and hospital anxiety and depression (HAD) scores were obtained before and after treatment. Changes in the scores, rates of symptom remission, and adverse effects were compared between the two groups.

Results

After 2 weeks of treatment, the average decrease in GerdQ score in the combination group (4.04 ± 2.34) was significantly greater than that in the monotherapy group (3.34 ± 2.74; P < 0.05). Significant differences between the two groups were also found for changes in HAD anxiety scores (5.45 ± 2.41 vs 3.34 ± 2.43, P < 0.05), depression scores (5.47 ± 2.47 vs 3.00 ± 3.28, P < 0.05), and anxiety-depression scores (5.20 ± 2.71 vs 3.60 ± 2.56, P < 0.05). The remission of symptoms (eructation, abdominal pain, anorexia, and other accompanying symptoms) in the combination group was significantly better than that in the monotherapy group, and no significant difference in the incidence of adverse events was observed between the two groups.

Conclusions

The combination therapy has better efficacy than the monotherapy in improving the symptoms of gastroesophageal reflux in patients with emotional disorders. In addition, this combination treatment is safe, with a low incidence of adverse events.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.